Fisher & Paykel Healthcare

Call Directions Website

Fisher & Paykel Healthcare We are a leading designer, manufacturer and marketer of products for use in respiratory care, acute care, and the treatment of obstructive sleep apnea.

Fisher & Paykel commenced business in 1934 as an importer of refrigerators and washing machines. In 1938 F&P started manufacturing white-ware under license to several major international appliance companies and in the mid-1960s moved to manufacturing products using in-house technology. The involvement in healthcare started in the late 1960s when F&P sought involvement in a business that could benefit from their growing manufacturing and electronic expertise. A prototype respiratory humidifier, developed in New Zealand for use with patients needing ventilation in hospital intensive care situations, was taken to production by F&P. Since then we have consistently developed innovations to improve patient care and developed world-wide distribution for these products. On 14 November 2001, as part of a reorganisation, Fisher & Paykel Industries Limited was renamed Fisher & Paykel Healthcare Corporation Limited and a new company, Fisher & Paykel Appliances Holdings Limited, was established to own F&P’s appliances and finance business. In connection with the reorganisation, Fisher & Paykel Healthcare Corporation Limited listed on the Australian and New Zealand Stock Exchanges and NASDAQ. In February 2003 the NASDAQ listing was terminated.

23/10/2026

A T-piece resuscitator can be used during neonatal resuscitation to provide consistent and controlled delivery of PEEP. Resuscitation guidelines recommend delivering PEEP whenever positive pressure ventilation is required in the delivery room. Research shows that providing PEEP when initiating ventilation may help to establish and maintain functional residual capacity, reduce delivery room intubation rates and the incidence of lung injury as well as improve the response to surfactant.

Find out more about neonatal T-piece resuscitation here: https://ap1.hubs.ly/H01phVz0

Products may not be available in all countries. Please consult the Instructions for Use (IFU) for each device for more information.

19/10/2026

Want to practice setting a patient up on Nasal High Flow therapy?

Our patient scenarios let you change flow rate, titrate oxygen and swap therapies - all before the device reaches the patient.

Have a go now: https://ap1.hubs.ly/H01q5sY0

05/10/2026

Short on time?

This will only take a minute. F&P Micro Moments answer your questions about Nasal High Flow therapy.

Watch now: https://ap1.hubs.ly/H01pX2s0

02/10/2026

The F&P Education Hub is your go-to resource for the latest webinars, courses and videos for respiratory care.

See what's available now: https://ap1.hubs.ly/H01pVpb0

29/09/2026

RSV season is almost here. To support therapy success with nasal high flow, initiate treatment early and prescribe flows based on patient weight and respiratory demand. Setting the correct flows is simple with the intuitive touch screen of the Airvo™ 3 System.

Click here to learn how the Airvo 3 System can help improve outcomes for pediatric patients in your hospital: https://ap1.hubs.ly/H01phTh0

Products may not be available in all countries. Please consult the Instructions for Use (IFU) for each device for more information.

12/08/2026

The RENOVATE Randomized Clinical Trial (JAMA, 2024), a multicenter study that comprised 1766 patients, found high-flow nasal oxygen to be significantly more comfortable than NIV. Curious about this and other key research findings? Visit our webpage to learn more and download our infographic, which will put the core details about this latest research in your hands.

https://ap1.hubs.ly/H01g8P20

11/08/2026

Want to know more about Nasal High Flow?

This animated series answers common questions like how it works, how to set it up and how to align your practice with the clinical evidence.

Watch the series and

https://ap1.hubs.ly/H016Fn00

04/08/2026

The RENOVATE Randomized Clinical Trial (JAMA, 2024) found that high-flow nasal oxygen is non-inferior to non-invasive ventilation for rates of endotracheal intubation or death at seven days in four acute respiratory care patient groups.

For more details and other key research findings, visit our webpage. There, you can download an infographic that contains the core research details.

https://ap1.hubs.ly/H01b9Jf0

28/07/2026

Why does the design matter?

Nasal high flow (NHF) therapy delivers heated, humidified air and oxygen at high flows to spontaneously breathing infants, making it a gentle and effective option.

A well-designed NHF interface ensures adequate flow delivery, reduces CO2 rebreathing, and supports mucosal health, helping to minimize complications such as nasal trauma.

Learn more about how Optiflow™ Junior 2 has been thoughtfully designed with the unique needs of neonates, infants and children in mind, at the link below:

https://ap1.hubs.ly/H015-710

*Products may not be available in all countries. Please consult the Instructions for Use (IFU) for each device for more information.

Address

15 Maurice Paykel Place, East Tamaki
Auckland
2013

Telephone

+64 9 574 0100

Website

Alerts

Be the first to know and let us send you an email when Fisher & Paykel Healthcare posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category